Calithera Biosciences (NASDAQ: CALA) reported Q3 EPS of ($0.49), versus ($16.85) reported last year.

Anticipated Upcoming Milestones

• Hematologic Phase 1 clinical trial data by year end 2015
• Initiation of six CB-839 combination expansion cohorts by year end 2015
• CB-839 combination therapy data in mid-2016
• Filing of investigational new drug application (IND) for arginase inhibitor CB-1158 in the first half of 2016

Guidance:

Calithera is updating its guidance of its cash, cash equivalents and investments to be at least $70 million at the end of 2015, exclusive of any license milestone payments or funds arising from any additional new collaborations or partnerships, equity financings or other new sources.

For earnings history and earnings-related data on Calithera Biosciences (CALA) click here.